Golara Honari

Golara Honari

Auto-generated profile, based on publicly available information

Golara Honari

Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
ESEric L. Simpson
Eric L. Simpson
JSJonathan Silverberg
Jonathan Silverberg
MWMargitta Worm
Margitta Worm
GHGolara Honari
Golara Honari
KMKoji Masuda
Koji Masuda
ABAshish Bansal
Ashish Bansal
Despite high disease burden, systemic treatment options for patients with atopic hand and/or foot dermatitis (H/F AD) are limited. To evaluate efficacy and safety of dupilumab in H/F AD using specific instruments for assessing disease severity on hands and feet. In this multicenter phase 3 trial, adults and adolescents with moderate-to-severe H/F AD were randomized to dupilumab monotherapy (regimen approved for generalized AD), or matched placebo. The primary endpoint was proportion of patients achieving Hand and Foot Investigator's Global Assessment score 0 or 1 at week 16. Secondary prespecified endpoints assessed the severity and extent of signs, symptom intensity (itch, pain), quality of life, and sleep. A total of 133 patients (adults = 106, adolescents = 27) were randomized to dupilumab (n = 67) or placebo (n = 66). At week 16, significantly more patients receiving dupilumab (n = 27) than placebo (n = 11) achieved Hand and Foot Investigator's Global Assessment score 0 or 1 (40.3% vs 16.7%; P = .003). All other prespecified endpoints were met. Safety was consistent with the known AD dupilumab profile. Short-term, 16-week treatment period. Dupilumab monotherapy resulted in significant improvements across different domains of H/F AD with acceptable safety, supporting dupilumab as a systemic treatment approach for this often difficult to treat condition.

7 April 2021 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
WCW.H. Chan
W.H. Chan
RSR. Srivastava
R. Srivastava
NDN. Damaraju
N. Damaraju
HDH. Do
H. Do
GBG. Burnett
G. Burnett
KSKavita Y. Sarin
Kavita Y. Sarin

1 March 2025 in Dermatitis®
Verified
Journal Article
Closed access
CYChristopher G. Youn
Christopher G. Youn
GBGordon H. Bae
Gordon H. Bae
GHGolara Honari
Golara Honari
JCJennifer K. Chen
Jennifer K. Chen
KSKavita Y. Sarin
Kavita Y. Sarin
DSDawn H. Siegel
Dawn H. Siegel
Abstracts: Background: Pediatric atopic dermatitis (AD) can pose a significant financial burden to families. However, no studies exist that assess the impact of pediatric AD on health care access/affordability at the parental level. Objective: Explore the effects of childhood AD on parental access to health care and the socioeconomic factors that might exacerbate these problems. Methods:: The National Health Interview Survey was used to analyze 48,329,314 participants who answered the validated question on pediatric AD. Multivariable logistic regression analyses were performed to assess the association between pediatric AD and parental access to care. Results:: Parents of children with AD were more likely to have difficulty accessing prescription medications (aOR: 1.47; [95% CI 1.31–1.65]), follow-up care (1.36; [95% CI 1.17–1.57]), specialist care (aOR: 1.53; [95% CI 1.33–1.75]), and more likely to purchase medications from abroad (aOR: 1.35; [95% CI 1.09–1.67]) relative to their counterparts with children without AD. Within the AD cohort, uninsured or lower income participants had higher odds of facing these barriers to care. Conclusions:: Parents of children with AD are more likely to face barriers in health care access, and significant disparities exist based on sociodemographic characteristics.

1 September 2021 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
CPChristine Pham
Christine Pham
MJMargit Juhasz
Margit Juhasz
JLJessica Lin
Jessica Lin
GHGolara Honari
Golara Honari
NMNatasha Mesinkovska
Natasha Mesinkovska

1 November 2025 in Dermatitis®
Verified
Journal Article
Closed access
SRShawheen J. Rezaei
Shawheen J. Rezaei
GHGolara Honari
Golara Honari
JCJennifer K. Chen
Jennifer K. Chen

17 March 2017
Verified
Book Chapter
Closed access
GHGolara Honari
Golara Honari
HMHoward Maibach
Howard Maibach